Navigation Links
Astellas/GlaxoSmithKline's Vesicare Has Advantages Over Pfizer's Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
Date:4/3/2008

Superior Side-Effect Profile Earns Vesicare Gold Standard Status Over Sales-Leading Detrol LA/Detrusitol XL, According to a New Report from

Decision Resources

WALTHAM, Mass., April 3, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on the reduction of urge urinary incontinence episodes (and the resulting improvement in a patient's quality of life) is the attribute that most influences urologists' prescribing decisions in the treatment of urge urinary incontinence. Clinical data and expert opinion show that Astellas/GlaxoSmithKline's Vesicare has advantages in this attribute over the market sales leader, Pfizer's Detrol LA/ Detrusitol XL.

The new report entitled Urge Urinary Incontinence: Commercial Windfall Awaits the Treatment That Offers Significant Improvement in Dryness Rates finds that a drug offering a greater reduction in the number of urge urinary incontinence episodes per week over Detrol LA/Detrusitol XL would earn a 25 percent patient share in this market. The report also finds that, although Detrol LA/Detrusitol XL is the sales leader in the urge urinary market, the current and future gold standard treatment for the indication is Vesicare.

At doses that provide superior efficacy, clinical data and expert opinion indicate that Vesicare is superior to Detrol LA/Detrusitol XL and its successor, Pfizer's Toviaz, in its side-effect profile -- particularly on rates of dry mouth, an important cause for discontinuation of therapy.

"We do not expect any therapy under development for urge urinary incontinence to displace Vesicare as the clinical gold standard treatment," said Cindy Mundy, Ph.D., principal director at Decision Resources. "While some therapies in development for this indication hold promise, most of them earned inferior scores in efficacy, safety and tolerability, and/or delivery features when compared with Vesicare."

About the Report

Urge Urinary Incontinence: Commercial Windfall Awaits the Treatment That Offers Significant Improvement in Dryness Rates is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New Celebrity Introduces Students to Need, Advantages of Health Care Careers
2. Presentation at ISSN Highlights Soy Protein Advantages for Endurance Athletes
3. Creative work has health advantages, Population Research Center study shows
4. Cord Blood America Supports Trend From New York, California for States to Inform Parents of the Advantages of Umbilical Cord Blood Storage
5. New study shows promise in reducing surgical risks associated with surgical bleeding
6. Global Health Project targets reducing AIDS among Indias adolescents
7. Preventing or reducing enlarged heart decreases risk of heart failure
8. Acting Surgeon General Announces National Initiatives to Protect Children by Reducing Exposure to Secondhand Smoke
9. Safe Blood for Africa Foundations African Club 25 Greatly Reducing HIV Infections in African Youth
10. Breast cancer survivors optimistic, yet lack critical information on reducing recurrence
11. World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... bible in homes across the world. Yisrayl says this generation is a time like no ... to turn to the Bible. , Yisrayl says he does not want to sound like ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company ... January ECRM trade show to continue the marketing and distribution of its product, The ... for providing 400 percent better absorption than traditional vitamin C supplements. At the trade ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Lice Troopers, ... lice cases in families with school-aged children since the holiday season. , “It ... holidays with their families, sharing hugs and taking photos, which is the head-to-head gateway ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... International ... of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in ... bodybuilder and nutritional scientist who was determined to create a line of products that ...
(Date:1/20/2017)... California (PRWEB) , ... January 20, 2017 , ... "TransFlare ... to use inside of Final Cut Pro X," said Christina Austin - CEO of ... the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase ... The global anti-obesity drugs market is expected to ... the forecast period and CAGR of 38.7% in the second half ... a CAGR of 32.8% from 2016 to 2027. The market is ... $24,063 million in 2027. ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology: